Evidence map›Paper›PMID 25103488›Full record

ArticleThe Journal of antimicrobial chemotherapy2014

Does universal active MRSA surveillance influence anti-MRSA antibiotic use? A retrospective analysis of the treatment of patients admitted with suspicion of infection at Veterans Affairs Medical Centers between 2005 and 2010.

Makoto Jones, Benedikt Huttner, Molly Leecaster, Angela Huttner, Kavitha Damal, Windy Tanner, Christopher Nielson, Michael A Rubin, Matthew Bidwell Goetz, Karl Madaras-Kelly and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. A Methyl 4-Oxo-4-phenylbut-2-enoate withACS infectious diseases · 2016
    Article
  3. Trends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans With Pneumonia at 128 Medical Centers, 2006-2010.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Makoto JonesVA Salt Lake City Health Care System and University of Utah, Salt Lake City, UT, USA makoto.jones@va.gov.
Benedikt HuttnerVA Salt Lake City Health Care System and University of Utah, Salt Lake City, UT, USA.
Molly LeecasterVA Salt Lake City Health Care System and University of Utah, Salt Lake City, UT, USA.
Angela HuttnerVA Salt Lake City Health Care System and University of Utah, Salt Lake City, UT, USA.
Kavitha DamalVA Salt Lake City Health Care System and University of Utah, Salt Lake City, UT, USA.
Windy TannerUniversity of Utah Department of Family and Preventative Medicine, Salt Lake City, UT, USA.
Christopher NielsonVA Reno Medical Center and University of Nevada Reno, Reno, NV, USA.
Michael A RubinVA Salt Lake City Health Care System and University of Utah, Salt Lake City, UT, USA.
Matthew Bidwell GoetzVA Greater Los Angeles Health Care System and David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Karl Madaras-KellyClinical Pharmacy Service, Veterans Affairs Medical Center, Boise, ID, USA.
Matthew H SamoreVA Salt Lake City Health Care System and University of Utah, Salt Lake City, UT, USA.
VA Salt Lake City Healthcare System · USUniversity of Utah · USRenown Regional Medical Center · USVA Greater Los Angeles Healthcare System · USVeterans Health Administration · US

Funding

Intermountain Center of Excellence for Infection Prevention StrategiesU01CI000334 · CI · UNIVERSITY OF UTAH · PI SAMORE, MATTHEW H · 2006 to 2010
$2.0M
Canadian Institutes of Health Research HIR 09-001Canadian Institutes of Health Research HIR 09-003NCPDCID CDC HHS 5U01CI000334
6 · The paper itself

Abstract

objectivesAfter the implementation of an active surveillance programme for MRSA in US Veterans Affairs (VA) Medical Centers, there was an increase in vancomycin use. We investigated whether positive MRSA admission surveillance tests were associated with MRSA-positive clinical admission cultures and whether the availability of surveillance tests influenced prescribers' ability to match initial anti-MRSA antibiotic use with anticipated MRSA results from clinical admission cultures.

methodsAnalyses were based on barcode medication administration data, microbiology data and laboratory data from 129 hospitals between January 2005 and September 2010. Hospitalized patient admissions were included if clinical cultures were obtained and antibiotics started within 2 days of admission. Mixed-effects logistic regression was used to examine associations between positive MRSA admission cultures and (i) admission MRSA surveillance test results and (ii) initial anti-MRSA therapy.

resultsAmong 569,815 included admissions, positive MRSA surveillance tests were strong predictors of MRSA-positive admission cultures (OR 8.5; 95% CI 8.2-8.8). The negative predictive value of MRSA surveillance tests was 97.6% (95% CI 97.5%-97.6%). The diagnostic OR between initial anti-MRSA antibiotics and MRSA-positive admission cultures was 3.2 (95% CI 3.1-3.4) for patients without surveillance tests and was not significantly different for admissions with surveillance tests.

conclusionsThe availability of nasal MRSA surveillance tests in VA hospitals did not seem to improve the ability of prescribers to predict the necessity of initial anti-MRSA treatment despite the high negative predictive value of MRSA surveillance tests. Prospective trials are needed to establish the safety and effectiveness of using MRSA surveillance tests to guide antibiotic therapy.

Indexed as

Drug UtilizationEpidemiological MonitoringAnti-Bacterial AgentsDrug TherapyHospitals, VeteransHumansMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsUnited StatesAnti-Bacterial Agentsdefinitive treatmentempirical treatmentvancomycin

Identifiers

PMID25103488
PMCPMC4296187
OpenAlexW2157701270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.